Wells Fargo & Company Fennec Pharmaceuticals Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 9,997 shares of FENC stock, worth $60,081. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,997
Previous 9,695
3.12%
Holding current value
$60,081
Previous $59,000
16.95%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding FENC
# of Institutions
64Shares Held
14.9MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$24.5 Million0.57% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$14.5 Million27.51% of portfolio
-
Solas Capital Management, LLC Darien, CT1.92MShares$11.6 Million7.68% of portfolio
-
Dg Capital Management, LLC New York, NY1.52MShares$9.15 Million4.41% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$7.14 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $157M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...